ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.

Roger B Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.